1[1]Bullingham R,Monroe S,Nicholls A,et al.Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration [J].J Clin Pharmacol,1996,36(4):315-324.
2[2]Shipkava M,Niedmann PD,Armstrong VM,et al.Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure [J].Clin Chem,1998,44(7):1481-1488.
3[3]Sugioka N,Odani H,Ohta T,et al.Determination of a new immunosuppressant,mycophenolate mofetil ,and its active metabolite,mycophenolic acid,in rat and human body fluids by high-performance liquid chromatography [J].J Chromatogr B Biomed Appl,1994,654(2):249-256.
4The tricontinental mycophenolate mofetil transplantation study group.A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation[].Transplantation.1996
5Langman LJ,LeGatt DF,Yatscoff RW.Blood distribution of mycophenolic acid[].Therapeutic Drug Monitoring.1994
6Pirsch JD,Sollinger HW.Mycophenolate mofetil-clinical and experimental experience[].Therapeutic Drug Monitoring.1996
7Nowak I,Shaw LM.Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity[].Therapeutic Drug Monitoring.1997
